Heart failure & cardiomyopathiesCohort study
Real-world evidence with dapagliflozin in heart failure with reduced ejection fraction in Central Eastern Europe and the Baltic region (EVOLUTION-HF Central Eastern Europe and the Baltic Area (CEE-BA) Study)
- multicentre, multi-country, observational, longitudinal study
- 102 centres in Bulgaria, Croatia, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, and Slovenia
- prospective follow-up continuing up to 12 months
Authors' conclusion
This large non-interventional study provides a contemporary perspective of the treatments used in HFrEF over 1-year follow-up. Despite high dapagliflozin persistence rates, a low proportion of patients received complete guideline-directed medical therapy in optimal doses. Improvement of HF management decisions across the CEE-BA region is warranted.
Study context
- Population
- Patients with HFrEF initiated on dapagliflozin in clinical practice in 9 countries from Central Eastern Europe and the Baltic Area (CEE-BA)patients with HFrEF included in the full analysis set
- Participants
- 1,131 patients
Main finding
As reported in the abstract
- Ischaemic aetiology
- 52%
- Mean left ventricular ejection fraction
- 32%
- Atrial fibrillation
- 46%
- Type 2 diabetes
- 37%
- Chronic kidney disease
- 29%
Observational data: associations, not effects.
Further findings
Concomitant HFrEF therapy at dapagliflozin initiation · At the time of dapagliflozin initiation
- Any combination of renin-angiotensin-aldosterone system inhibitor (RAASi), beta-blocker (BB), or mineralocorticoid receptor antagonists (MRA)
- 93%
- All three classes plus dapagliflozin
- 60%
- Optimal dose, any RAASi
- 14%
- Optimal dose, BB
- 17%
- Optimal dose, MRA
- 25%
- Dapagliflozin dose
- 10 mg/day
Maintenance of dapagliflozin treatment · 6- and 12-month follow-up
- 6 months
- 95%
- 12 months
- 96%
- Median time to discontinuation of dapagliflozin has not been reached
Patients receiving all four classes recommended in HFrEF · over the study period
- Remained stable over the study period
Adverse event reporting
- Adverse events were reported spontaneously, as in routine clinical practice in each centre.
Original publication
Summarised from the published abstract; every number is checked against it